AAPL,Apple to unveil iPhone 6 in August, earlier than expected -reportMarket Chatter- Corporate finance press digestCORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallREFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.   REFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)REFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.    US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallREFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.   REFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)REFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.   (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallREFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.   REFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)REFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.     CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallREFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.   REFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)REFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.    US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallREFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.   REFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)REFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.   (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallREFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.   REFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)REFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.    May 9 The following corporate finance-related stories were reported by media:CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallREFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.   REFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)REFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.    US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallREFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.   REFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)REFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.   (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallREFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.   REFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)REFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.      Market Chatter- Corporate finance press digestCORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallREFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.   REFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)REFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.    US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallREFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.   REFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)REFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.   (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallREFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.   REFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)REFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.     CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallREFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.   REFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)REFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.    US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallREFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.   REFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)REFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.   (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallREFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.   REFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)REFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.    May 9 The following corporate finance-related stories were reported by media:CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallREFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.   REFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)REFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.    US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallREFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.   REFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)REFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.   (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallREFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.   REFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)REFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.     TAIPEI, May 9 Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.Market Chatter- Corporate finance press digestCORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallREFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.   REFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)REFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.    US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallREFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.   REFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)REFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.   (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallREFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.   REFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)REFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.     CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallREFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.   REFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)REFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.    US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallREFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.   REFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)REFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.   (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallREFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.   REFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)REFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.    May 9 The following corporate finance-related stories were reported by media:CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallREFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.   REFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)REFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.    US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallREFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.   REFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)REFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.   (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallREFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.   REFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)REFILE-UPDATE 2-Apple close to buying Beats for $3.2 bln -sourceApple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.  Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources. (In 16th paragraph, corrects Apple CEO's last name to Cook instead of Cooks)Apple to unveil iPhone 6 in August, earlier than expected: report TAIPEI Apple Inc will unveil the next incarnation of its popular iPhone series in August, one month earlier than industry watchers were generally expecting, Taiwanese media reported on Friday citing unidentified supply-chain sources.      
BSX,Boston Scientific gets subpoena over defibrillators May 8 Medical device maker Boston Scientific Corp said it received a subpoena this week from the Department of Health and Human Services seeking information about the performance of some of its implanted defibrillators. 
GPS,CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in four (Corrects to show earnings data through Thursday morning, not Wednesday) 
GE,Juncker says France shouldn't blame its woes on euroFrance wants Areva to buy Alstom wind unit if GE wins bid-paperUPDATE 1-France wants Areva to buy Alstom wind unit if GE wins bid-paper * Even together, the two would be small player in offshore   (Adds EWA data, industry background)  UPDATE 1-France wants Areva to buy Alstom wind unit if GE wins bid-paper * Even together, the two would be small player in offshore   (Adds EWA data, industry background) PARIS, May 9 France wants state-controlled nuclear group Areva to take over Alstom's offshore wind turbine unit if General Electric's bid for Alstom succeeds, a French paper reported on Friday.UPDATE 1-France wants Areva to buy Alstom wind unit if GE wins bid-paper * Even together, the two would be small player in offshore   (Adds EWA data, industry background)   France wants Areva to buy Alstom wind unit if GE wins bid-paperUPDATE 1-France wants Areva to buy Alstom wind unit if GE wins bid-paper * Even together, the two would be small player in offshore   (Adds EWA data, industry background)  UPDATE 1-France wants Areva to buy Alstom wind unit if GE wins bid-paper * Even together, the two would be small player in offshore   (Adds EWA data, industry background) PARIS, May 9 France wants state-controlled nuclear group Areva to take over Alstom's offshore wind turbine unit if General Electric's bid for Alstom succeeds, a French paper reported on Friday.UPDATE 1-France wants Areva to buy Alstom wind unit if GE wins bid-paper * Even together, the two would be small player in offshore   (Adds EWA data, industry background)  BERLIN France's economic woes are the result of poor policy choices at home and Paris should stop blaming its problems on the strength of the euro, Jean-Claude Juncker, the center-right candidate for European Commission president, told Reuters.France wants Areva to buy Alstom wind unit if GE wins bid-paperUPDATE 1-France wants Areva to buy Alstom wind unit if GE wins bid-paper * Even together, the two would be small player in offshore   (Adds EWA data, industry background)  UPDATE 1-France wants Areva to buy Alstom wind unit if GE wins bid-paper * Even together, the two would be small player in offshore   (Adds EWA data, industry background) PARIS, May 9 France wants state-controlled nuclear group Areva to take over Alstom's offshore wind turbine unit if General Electric's bid for Alstom succeeds, a French paper reported on Friday.UPDATE 1-France wants Areva to buy Alstom wind unit if GE wins bid-paper * Even together, the two would be small player in offshore   (Adds EWA data, industry background)   
GS,Mitsubishi UFJ may bid for BNY Mellon's Trust Unit: BloombergGoldman says its overseas hiring practices being investigated May 9 Goldman Sachs Group Inc disclosed on Friday that it was being investigated over its hiring practices outside the United States.  Goldman says its overseas hiring practices being investigated May 9 Goldman Sachs Group Inc disclosed on Friday that it was being investigated over its hiring practices outside the United States. Mitsubishi UFJ Financial Group Inc , Japan's biggest lender, is considering bidding for the corporate trust arm of Bank of New York Mellon Corp , Bloomberg reported on Friday, citing unidentified people with knowledge of the matter.Goldman says its overseas hiring practices being investigated May 9 Goldman Sachs Group Inc disclosed on Friday that it was being investigated over its hiring practices outside the United States.  
OMC,WATCH LIVE: Reuters Today - Publicis, Omnicom call off mergerPublicis CEO says board backs him after Omnicom deal failsUPDATE 1-Publicis CEO says board backs him after Omnicom deal failsPublicis CEO says board backs him after Omnicom deal failsCORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video      CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     PARIS Advertising agency Publicis will probably return money to shareholders and pursue smaller acquisitions this year as it seeks to get back on track after the failure of a $35 billion merger with U.S. peer Omnicom.CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video       Publicis CEO says board backs him after Omnicom deal failsCORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video      CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     PARIS Advertising agency Publicis will probably return money to shareholders and pursue smaller acquisitions this year as it seeks to get back on track after the failure of a $35 billion merger with U.S. peer Omnicom.CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video      * Levy says no large acquisitions in works, few small onesPublicis CEO says board backs him after Omnicom deal failsCORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video      CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     PARIS Advertising agency Publicis will probably return money to shareholders and pursue smaller acquisitions this year as it seeks to get back on track after the failure of a $35 billion merger with U.S. peer Omnicom.CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video        UPDATE 1-Publicis CEO says board backs him after Omnicom deal failsPublicis CEO says board backs him after Omnicom deal failsCORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video      CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     PARIS Advertising agency Publicis will probably return money to shareholders and pursue smaller acquisitions this year as it seeks to get back on track after the failure of a $35 billion merger with U.S. peer Omnicom.CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video       Publicis CEO says board backs him after Omnicom deal failsCORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video      CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     PARIS Advertising agency Publicis will probably return money to shareholders and pursue smaller acquisitions this year as it seeks to get back on track after the failure of a $35 billion merger with U.S. peer Omnicom.CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video      * Levy says no large acquisitions in works, few small onesPublicis CEO says board backs him after Omnicom deal failsCORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video      CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     PARIS Advertising agency Publicis will probably return money to shareholders and pursue smaller acquisitions this year as it seeks to get back on track after the failure of a $35 billion merger with U.S. peer Omnicom.CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video       PARIS, May 9 Publicis Chief Executive Maurice Levy said the board of the advertising group backed him after a $35 billion merger with U.S. peer Omnicom fell apart because of a power struggle in what was billed a merger of equals.UPDATE 1-Publicis CEO says board backs him after Omnicom deal failsPublicis CEO says board backs him after Omnicom deal failsCORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video      CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     PARIS Advertising agency Publicis will probably return money to shareholders and pursue smaller acquisitions this year as it seeks to get back on track after the failure of a $35 billion merger with U.S. peer Omnicom.CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video       Publicis CEO says board backs him after Omnicom deal failsCORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video      CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     PARIS Advertising agency Publicis will probably return money to shareholders and pursue smaller acquisitions this year as it seeks to get back on track after the failure of a $35 billion merger with U.S. peer Omnicom.CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video      * Levy says no large acquisitions in works, few small onesPublicis CEO says board backs him after Omnicom deal failsCORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video      CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     PARIS Advertising agency Publicis will probably return money to shareholders and pursue smaller acquisitions this year as it seeks to get back on track after the failure of a $35 billion merger with U.S. peer Omnicom.CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video         Publicis CEO says board backs him after Omnicom deal failsUPDATE 1-Publicis CEO says board backs him after Omnicom deal failsPublicis CEO says board backs him after Omnicom deal failsCORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video      CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     PARIS Advertising agency Publicis will probably return money to shareholders and pursue smaller acquisitions this year as it seeks to get back on track after the failure of a $35 billion merger with U.S. peer Omnicom.CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video       Publicis CEO says board backs him after Omnicom deal failsCORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video      CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     PARIS Advertising agency Publicis will probably return money to shareholders and pursue smaller acquisitions this year as it seeks to get back on track after the failure of a $35 billion merger with U.S. peer Omnicom.CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video      * Levy says no large acquisitions in works, few small onesPublicis CEO says board backs him after Omnicom deal failsCORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video      CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     PARIS Advertising agency Publicis will probably return money to shareholders and pursue smaller acquisitions this year as it seeks to get back on track after the failure of a $35 billion merger with U.S. peer Omnicom.CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video        UPDATE 1-Publicis CEO says board backs him after Omnicom deal failsPublicis CEO says board backs him after Omnicom deal failsCORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video      CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     PARIS Advertising agency Publicis will probably return money to shareholders and pursue smaller acquisitions this year as it seeks to get back on track after the failure of a $35 billion merger with U.S. peer Omnicom.CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video       Publicis CEO says board backs him after Omnicom deal failsCORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video      CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     PARIS Advertising agency Publicis will probably return money to shareholders and pursue smaller acquisitions this year as it seeks to get back on track after the failure of a $35 billion merger with U.S. peer Omnicom.CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video      * Levy says no large acquisitions in works, few small onesPublicis CEO says board backs him after Omnicom deal failsCORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video      CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     PARIS Advertising agency Publicis will probably return money to shareholders and pursue smaller acquisitions this year as it seeks to get back on track after the failure of a $35 billion merger with U.S. peer Omnicom.CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video       PARIS, May 9 Publicis Chief Executive Maurice Levy said the board of the advertising group backed him after a $35 billion merger with U.S. peer Omnicom fell apart because of a power struggle in what was billed a merger of equals.UPDATE 1-Publicis CEO says board backs him after Omnicom deal failsPublicis CEO says board backs him after Omnicom deal failsCORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video      CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     PARIS Advertising agency Publicis will probably return money to shareholders and pursue smaller acquisitions this year as it seeks to get back on track after the failure of a $35 billion merger with U.S. peer Omnicom.CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video       Publicis CEO says board backs him after Omnicom deal failsCORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video      CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     PARIS Advertising agency Publicis will probably return money to shareholders and pursue smaller acquisitions this year as it seeks to get back on track after the failure of a $35 billion merger with U.S. peer Omnicom.CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video      * Levy says no large acquisitions in works, few small onesPublicis CEO says board backs him after Omnicom deal failsCORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video      CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     PARIS Advertising agency Publicis will probably return money to shareholders and pursue smaller acquisitions this year as it seeks to get back on track after the failure of a $35 billion merger with U.S. peer Omnicom.CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video        May 9 WATCH LIVE: http://link.reuters.com/bat29vPublicis CEO says board backs him after Omnicom deal failsUPDATE 1-Publicis CEO says board backs him after Omnicom deal failsPublicis CEO says board backs him after Omnicom deal failsCORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video      CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     PARIS Advertising agency Publicis will probably return money to shareholders and pursue smaller acquisitions this year as it seeks to get back on track after the failure of a $35 billion merger with U.S. peer Omnicom.CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video       Publicis CEO says board backs him after Omnicom deal failsCORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video      CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     PARIS Advertising agency Publicis will probably return money to shareholders and pursue smaller acquisitions this year as it seeks to get back on track after the failure of a $35 billion merger with U.S. peer Omnicom.CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video      * Levy says no large acquisitions in works, few small onesPublicis CEO says board backs him after Omnicom deal failsCORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video      CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     PARIS Advertising agency Publicis will probably return money to shareholders and pursue smaller acquisitions this year as it seeks to get back on track after the failure of a $35 billion merger with U.S. peer Omnicom.CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video        UPDATE 1-Publicis CEO says board backs him after Omnicom deal failsPublicis CEO says board backs him after Omnicom deal failsCORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video      CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     PARIS Advertising agency Publicis will probably return money to shareholders and pursue smaller acquisitions this year as it seeks to get back on track after the failure of a $35 billion merger with U.S. peer Omnicom.CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video       Publicis CEO says board backs him after Omnicom deal failsCORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video      CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     PARIS Advertising agency Publicis will probably return money to shareholders and pursue smaller acquisitions this year as it seeks to get back on track after the failure of a $35 billion merger with U.S. peer Omnicom.CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video      * Levy says no large acquisitions in works, few small onesPublicis CEO says board backs him after Omnicom deal failsCORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video      CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     PARIS Advertising agency Publicis will probably return money to shareholders and pursue smaller acquisitions this year as it seeks to get back on track after the failure of a $35 billion merger with U.S. peer Omnicom.CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video       PARIS, May 9 Publicis Chief Executive Maurice Levy said the board of the advertising group backed him after a $35 billion merger with U.S. peer Omnicom fell apart because of a power struggle in what was billed a merger of equals.UPDATE 1-Publicis CEO says board backs him after Omnicom deal failsPublicis CEO says board backs him after Omnicom deal failsCORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video      CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     PARIS Advertising agency Publicis will probably return money to shareholders and pursue smaller acquisitions this year as it seeks to get back on track after the failure of a $35 billion merger with U.S. peer Omnicom.CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video       Publicis CEO says board backs him after Omnicom deal failsCORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video      CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     PARIS Advertising agency Publicis will probably return money to shareholders and pursue smaller acquisitions this year as it seeks to get back on track after the failure of a $35 billion merger with U.S. peer Omnicom.CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video      * Levy says no large acquisitions in works, few small onesPublicis CEO says board backs him after Omnicom deal failsCORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video      CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     PARIS Advertising agency Publicis will probably return money to shareholders and pursue smaller acquisitions this year as it seeks to get back on track after the failure of a $35 billion merger with U.S. peer Omnicom.CORRECTED-US STOCKS-Futures dip; Nasdaq set for worst weekly loss in fourUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video     US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    (Corrects to show earnings data through Thursday morning, not Wednesday)US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fallCORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video    CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)CORRECTED-UPDATE 6-Battle for control destroyed $35 bln Omnicom-Publicis mergerBattle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video   Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video  (Corrects paragraph 3 to show Omnicom CEO as John Wren, not John Levy)Battle for control destroyed $35-billion Omnicom-Publicis merger LONDON/NEW YORK/PARIS The $35-billion merger of U.S.-based Omnicom and France's Publicis collapsed on Friday after a battle for control destroyed plans to create the world's largest advertising agency. |Video         
PFE,UPDATE 1-Maryland, Delaware governors concerned about Pfizer-Astra dealMaryland, Delaware governors concerned about Pfizer-Astra dealINDIA PRESS-Pfizer, Roche end association with US-India Business Council-Economic TimesBritain wants binding pledges from Pfizer on AstraZeneca bidUPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers      UPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.UPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers       Britain wants binding pledges from Pfizer on AstraZeneca bidUPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers      UPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.UPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers      Note: Reuters has not verified this story and does not vouch for its accuracy.   (Compiled by Aby Jose Koilparambil in Bangalore)Britain wants binding pledges from Pfizer on AstraZeneca bidUPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers      UPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.UPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers        INDIA PRESS-Pfizer, Roche end association with US-India Business Council-Economic TimesBritain wants binding pledges from Pfizer on AstraZeneca bidUPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers      UPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.UPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers       Britain wants binding pledges from Pfizer on AstraZeneca bidUPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers      UPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.UPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers      Note: Reuters has not verified this story and does not vouch for its accuracy.   (Compiled by Aby Jose Koilparambil in Bangalore)Britain wants binding pledges from Pfizer on AstraZeneca bidUPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers      UPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.UPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers       The governors of Maryland and Delaware on Thursday sent a letter to Pfizer Inc  Chief Executive Officer Ian Read "expressing deep concerns" about the pharmaceutical company's bid to acquire London-based AstraZeneca Plc .INDIA PRESS-Pfizer, Roche end association with US-India Business Council-Economic TimesBritain wants binding pledges from Pfizer on AstraZeneca bidUPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers      UPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.UPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers       Britain wants binding pledges from Pfizer on AstraZeneca bidUPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers      UPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.UPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers      Note: Reuters has not verified this story and does not vouch for its accuracy.   (Compiled by Aby Jose Koilparambil in Bangalore)Britain wants binding pledges from Pfizer on AstraZeneca bidUPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers      UPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.UPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers         Maryland, Delaware governors concerned about Pfizer-Astra dealINDIA PRESS-Pfizer, Roche end association with US-India Business Council-Economic TimesBritain wants binding pledges from Pfizer on AstraZeneca bidUPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers      UPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.UPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers       Britain wants binding pledges from Pfizer on AstraZeneca bidUPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers      UPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.UPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers      Note: Reuters has not verified this story and does not vouch for its accuracy.   (Compiled by Aby Jose Koilparambil in Bangalore)Britain wants binding pledges from Pfizer on AstraZeneca bidUPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers      UPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.UPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers        INDIA PRESS-Pfizer, Roche end association with US-India Business Council-Economic TimesBritain wants binding pledges from Pfizer on AstraZeneca bidUPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers      UPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.UPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers       Britain wants binding pledges from Pfizer on AstraZeneca bidUPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers      UPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.UPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers      Note: Reuters has not verified this story and does not vouch for its accuracy.   (Compiled by Aby Jose Koilparambil in Bangalore)Britain wants binding pledges from Pfizer on AstraZeneca bidUPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers      UPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.UPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers       The governors of Maryland and Delaware on Thursday sent a letter to Pfizer Inc  Chief Executive Officer Ian Read "expressing deep concerns" about the pharmaceutical company's bid to acquire London-based AstraZeneca Plc .INDIA PRESS-Pfizer, Roche end association with US-India Business Council-Economic TimesBritain wants binding pledges from Pfizer on AstraZeneca bidUPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers      UPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.UPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers       Britain wants binding pledges from Pfizer on AstraZeneca bidUPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers      UPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.UPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers      Note: Reuters has not verified this story and does not vouch for its accuracy.   (Compiled by Aby Jose Koilparambil in Bangalore)Britain wants binding pledges from Pfizer on AstraZeneca bidUPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers      UPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.UPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers        May 8 The governors of Maryland and Delaware on Thursday sent a letter to Pfizer Inc Chief Executive Officer Ian Read "expressing deep concerns" about the pharmaceutical company's bid to acquire London-based AstraZeneca Plc.Maryland, Delaware governors concerned about Pfizer-Astra dealINDIA PRESS-Pfizer, Roche end association with US-India Business Council-Economic TimesBritain wants binding pledges from Pfizer on AstraZeneca bidUPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers      UPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.UPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers       Britain wants binding pledges from Pfizer on AstraZeneca bidUPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers      UPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.UPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers      Note: Reuters has not verified this story and does not vouch for its accuracy.   (Compiled by Aby Jose Koilparambil in Bangalore)Britain wants binding pledges from Pfizer on AstraZeneca bidUPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers      UPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.UPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers        INDIA PRESS-Pfizer, Roche end association with US-India Business Council-Economic TimesBritain wants binding pledges from Pfizer on AstraZeneca bidUPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers      UPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.UPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers       Britain wants binding pledges from Pfizer on AstraZeneca bidUPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers      UPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.UPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers      Note: Reuters has not verified this story and does not vouch for its accuracy.   (Compiled by Aby Jose Koilparambil in Bangalore)Britain wants binding pledges from Pfizer on AstraZeneca bidUPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers      UPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.UPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers       The governors of Maryland and Delaware on Thursday sent a letter to Pfizer Inc  Chief Executive Officer Ian Read "expressing deep concerns" about the pharmaceutical company's bid to acquire London-based AstraZeneca Plc .INDIA PRESS-Pfizer, Roche end association with US-India Business Council-Economic TimesBritain wants binding pledges from Pfizer on AstraZeneca bidUPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers      UPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.UPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers       Britain wants binding pledges from Pfizer on AstraZeneca bidUPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers      UPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.UPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers      Note: Reuters has not verified this story and does not vouch for its accuracy.   (Compiled by Aby Jose Koilparambil in Bangalore)Britain wants binding pledges from Pfizer on AstraZeneca bidUPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers      UPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.UPDATE 1-Britain wants binding pledges from Pfizer on AstraZeneca bidBritain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers     Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    LONDON, May 9 The British government needs to be confident that any commitments made by Pfizer in a proposed takeover of AstraZeneca are binding, British Deputy Prime Minister Nick Clegg said on Friday.Britain wants binding pledges from Pfizer on AstraZeneca bidPfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers    Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   LONDON The British government needs to be confident that any commitments made by Pfizer  in a proposed takeover of AstraZeneca  are binding, British Deputy Prime Minister Nick Clegg said on Friday.Pfizer signs rare diseases deal with UK universitiesPfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers   Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  LONDON, May 9 U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer signs rare diseases deal with UK universitiesPfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers  Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers LONDON U.S. drugmaker Pfizer, battling to buy British rival AstraZeneca, has struck a deal with leading British universities to hunt for new medicines to treat rare diseases.Pfizer under fire in Europe, U.S. as it weighs next Astra move * Pfizer may delay any new bid until after meeting UK lawmakers         
RL,Ralph Lauren sees 2015 revenues up 6-8 pct, warns of margin hitUS STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fall * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)  US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fall * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices) May 9 Ralph Lauren Corp said on Friday it expected global revenues to rise between 6 percent and 8 percent in fiscal 2015 but warned its operating margin would decline as it spends money to further build its network of stores.US STOCKS-Wall St to dip at open; Nasdaq set for 4th straight fall * Futures off: Dow 22 pts, S&P; 3 pts, Nasdaq 7.25 pts   (Adds Ralph Lauren, updates prices)  
RTN,Budget-strapped Israeli military banks on future US aid JERUSALEM, May 9 Budget-strapped Israel is pressing the United States to conclude a deal extending defence aid beyond 2017, when Washington's current $3 billion annual payouts to its Middle East ally expire, officials said on Friday. 
RCL,BRIEF-Royal Caribbean orders fourth Oasis-class vessel May 9 Royal Caribbean Cruises  :  * Says orders fourth Oasis-class cruise ship  * Says Oasis-class ship for delivery in 2018  * Says its projected capital expenditures for 2014, 2015, 2016, 2017 and 2018 are $1.4 billion, $1.4 billion, $2.2 billion, $0.3 billion and $1.5 billion, respectively, taking into account this order and existing ship orders 
BK,Mitsubishi UFJ may bid for BNY Mellon's Trust Unit -BloombergUPDATE 1-Mitsubishi UFJ may bid for BNY Mellon's Trust Unit - Bloomberg May 9 Mitsubishi UFJ Financial Group Inc , Japan's biggest lender, is considering bidding for the corporate trust arm of Bank of New York Mellon Corp, Bloomberg reported on Friday, citing unidentified people with knowledge of the matter.  UPDATE 1-Mitsubishi UFJ may bid for BNY Mellon's Trust Unit - Bloomberg May 9 Mitsubishi UFJ Financial Group Inc , Japan's biggest lender, is considering bidding for the corporate trust arm of Bank of New York Mellon Corp, Bloomberg reported on Friday, citing unidentified people with knowledge of the matter. May 9 Mitsubishi UFJ Financial Group Inc , Japan's biggest lender, is considering bidding for the corporate trust arm of Bank of New York Mellon Corp, Bloomberg reported on Friday citing unidentified people with knowledge of the matter.UPDATE 1-Mitsubishi UFJ may bid for BNY Mellon's Trust Unit - Bloomberg May 9 Mitsubishi UFJ Financial Group Inc , Japan's biggest lender, is considering bidding for the corporate trust arm of Bank of New York Mellon Corp, Bloomberg reported on Friday, citing unidentified people with knowledge of the matter.  
WMT,Wal-Mart should face lawsuit over Mexico operations -U.S. judge May 9 Wal-Mart Stores Inc should face a U.S. shareholder lawsuit accusing it of concealing suspected corruption at its Mexico operations, even after learning that a damaging media report was being prepared for publication, a federal judge said. 
